Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome Natural history by Murphy, Ross T. et al.
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PHypertrophic Cardiomyopathy
denosine Monophosphate-Activated
rotein Kinase Disease Mimicks Hypertrophic
ardiomyopathy and Wolff-Parkinson-White Syndrome
atural History
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lison Evans, PHD, Eyman Osman, BSC, Petros Syrris, PHD, Grainne Gorman, MRCPI,
ichael Farrell, FRCPI, Janice L. Holton, PHD, Michael G. Hanna, MD, Sian Hughes, PHD,
erry M. Elliott, MD, FACC, Calum A. MacRae, MB, CHB, William J. McKenna, MD, FACC
ondon, United Kingdom
OBJECTIVES The aim of this study was to investigate the clinical expression of adenosine monophosphate-
activated protein kinase (AMPK) gene mutations (PRKAG2) in adenosine monophosphate
(AMP) kinase disease based on 12 years follow-up of known mutation carriers and to define
the prevalence of PRKAG2 mutations in hypertrophic cardiomyopathy (HCM).
BACKGROUND Adenosine monophosphate-activated protein kinase gene mutations cause HCM with
Wolff-Parkinson-White syndrome and conduction disease.
METHODS Clinical evaluation of 44 patients with known AMP kinase disease was analyzed. Mutation
analysis of PRKAG2 was performed by fluorescent single-strand confirmation polymorphism
analysis and direct sequencing of abnormal conformers in 200 patients with HCM.
RESULTS Only one additional mutation was identified. The mean age at clinical diagnosis in the 45
gene carriers was 24 years (median 20 years, range 9 to 55 years). Symptoms of palpitation,
dypspnea, chest pain, or syncope were present in 31 (69%) gene carriers; 7 (15%) complained
of myalgia and had clinical evidence of proximal myopathy. Skeletal muscle biopsy showed
excess mitochondria and ragged red fibers with minimal glycogen accumulation. Disease
penetrance defined by typical electrocardiogram abnormalities was 100% by age 18 years.
Thirty-two of 41 adults (78%) had left ventricular hypertrophy (LVH) on echocardiography,
and progressive LVH was documented during follow-up. Survival was 91% at a mean
follow-up of 12.2 years. Progressive conduction disease required pacemaker implantation in
17 of 45 (38%) at a mean age of 38 years.
CONCLUSIONS The AMP kinase disease is uncommon in HCM and is characterized by progressive
conduction disease and cardiac hypertrophy and includes extracardiac manifestations such as
a skeletal myopathy, consistent with a systemic metabolic storage disease. Defects in
adenosine triphosphate utilization or in specific cellular substrates, rather than mere passive
deposition of amylopectin, may account for these clinical features. (J Am Coll Cardiol 2005;
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.11.05345:922–30) © 2005 by the American College of Cardiology Foundation
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pecent reports reveal that mutations in the gene for the 2
ubunit (PRKAG2) of adenosine monophosphate (AMP)-
ctivated protein kinase (AMPK) may cause left ventricular
ypertrophy (LVH) mimicking hypertrophic cardiomyopa-
hy (HCM) with electrophysiologic abnormalities (includ-
ng Wolff-Parkinson-White [WPW] syndrome and atrio-
entricular block) (1–3). AMP kinase acts as an enzymatic
odulator of adenosine triphosphate (ATP) sensitivity to
ellular energy requirements. Although murine models of
MP kinase disease have identified deposition of amylopec-
in in myocytes as a fundamental mechanism of disease (4),
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ccepted November 22, 2004.storage abnormality alone does not fully explain the
eterogeneous nature of the disorder in man.
Hypertrophic cardiomyopathy is caused by mutations in
everal genes encoding sarcomeric proteins affecting the
ontractile apparatus of the myocardium, although a unify-
ng molecular mechanism is still not established (5). Some
tudies suggest that hypertrophy develops as a consequence
f compensation for impaired contractile activity, but stud-
es of other sarcomeric gene mutations have demonstrated
nhanced contractile function (6). The effects of individual
utations may be exerted at many levels other than the
ontractile function of individual fibers. These include
isruption of sarcomere assembly, distortion of normal
ellular architecture, or dysregulation of the normal feed-
ack loops regulating the function for the intact heart.
everal murine models of HCM suggest that the hypertro-
hic response may be due to chronic inefficiency of energy
tilization by the heart. The isolation of disease-causing
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March 15, 2005:922–30 AMP Kinase Disease in Hypertrophic CardiomyopathyRKAG2 mutations led to suggestions that defects in a
entral sensing mechanism handling ATP utilization might
lso be important in the development of hypertrophy in
CM (7). We assessed the prevalence of PRKAG2 muta-
ions in a series of HCM probands, and in a selected cohort
f 100 HCM probands with conduction disease or pre-
xcitation. In addition, we describe the detailed 12-year
ollow-up of 45 patients with AMPK disease, and define the
elevance of this pathway to the wider HCM population.
ETHODS
enetic screening. We have previously identified 30 pa-
ients from two families with mutations in PRKAG2
Asn488Ile, Family H304, and Arg302Gln, Family H363)
2). After appropriate genetic counseling and written in-
ormed consent, 94 first- and second-degree relatives of the
dentified probands were offered genetic screening for the
dentified mutations.
Mutation analysis was performed in 100 selected consec-
tive HCM patients and in an additional 100 HCM
atients with evidence of premature sinoatrial or atrioven-
ricular conduction disease (n  68), with a short PR
nterval (n  20), or with features consistent with an
ccessory pathway on the surface electrocardiogram (ECG)
n  12) selected from a dedicated cardiomyopathy clinic at
t. George’s Hospital Medical School, London, United
ingdom, over a 12-year period, from a total HCM patient
opulation of 1,468 patients. Deoxyribonucleic acid was
xtracted from whole blood as described previously (2) and
hen subjected to analysis using fluorescent oligonucleotide
rimers (Sigma-Aldrich, Gillingham, United Kingdom)
omplementary to flanking intron sequences for all 16
rotein-encoding exons for polymerase chain reaction am-
lification. Primer sequences and polymerase chain reaction
onditions are available on request. The resultant polymer-
se chain reaction product was analyzed by conventional
ingle-strand confirmation polymorphism (standard 10%
olyacrylamide gel electrophoresis in 1  Tris-Borate-
DTA buffer at room temperature and post-electrophoresis
ilver staining) and abnormal conformers subjected to direct
equencing using an ABI 3100 sequencer (Applied Biosys-
ems Inc., Foster City, California). When a mutation was
dentified, a second blood sample from the affected patient
as reanalyzed to confirm the finding by single-strand
Abbreviations and Acronyms
AMP  adenosine monophosphate
AMPK  adenosine monophosphate-activated protein
kinase
HCM  hypertrophic cardiomyopathy
LVH  left ventricular hypertrophy
MLVWT  maximum left ventricular wall thickness
NYHA  New York Heart Association
WPW  Wolff-Parkinson-Whiteonfirmation polymorphism. We have previously shown o5% sensitivity and 97% specificity compared with direct
equencing for this method in mutation screening for HCM
8).
linical screening. We analyzed initial and follow-up
linical data on those probands and their relatives who had
utations in the 2 subunit of the AMPK gene (PRKAG2).
e have previously published the cardiac evaluation of 30
atients from two families and here present the broader
henotypic assessment and long-term follow-up on 45 gene
arriers from three families with mutations in PRKAG2
2,9). After written informed consent, all patients under-
ent standard investigative clinical assessment involving
linical history and examination, electrocardiogram, two-
imensional and Doppler echocardiographic assessment,
etabolic exercise testing, and 24-h Holter monitoring with
t least annual outpatient follow-up.
Ventricular pre-excitation on ECG was diagnosed on the
asis of a short PR interval (120 ms) with a widened QRS
omplex (110 ms) or with an abnormal initial QRS vector
a delta wave); ECGs typical of WPW were defined by the
resence of a short PR interval and a delta wave. Romhilt-
stes criteria for LVH on ECG were used (10). Sinus node
isease was defined by symptomatic bradycardia at rest 50
eats/min or symptomatic chronotropic incompetence on
xercise testing (11). Transthoracic two-dimensional and
oppler echocardiography was performed by a cardiomy-
pathy specialist in accordance with the recommendations
f the American Society of Echocardiography (12). Left
entricular hypertrophy was defined where maximal septal
r free wall thickness measured at least 13 mm in the
bsence of known acquired causes of LVH. The magnitude
nd distribution of LVH were assessed in the parasternal
hort-axis and confirmed in parasternal long-axis and apical
iews as previously described (13). Progression of hypertro-
hy was defined as an increase in maximum left ventricular
all thickness (MLVWT) 3 mm, and regression a de-
rease 3 mm. Impaired systolic function was defined
here percent fractional shortening was 25%. Patients
nderwent exercise testing on a bicycle ergometer (Sensor-
edics Ergometrics 800S, Bitz, Germany) using a ramp
rotocol of 10 to 15 W with respiratory gas sampling and
erial measurements of blood pressure during exercise. Peak
xygen consumption was defined as the highest peak oxygen
onsumption achieved during exercise. Invasive electro-
hysiologic studies were performed when symptoms sug-
ested sustained arrhythmias.
Full neurological assessment by a specialist neurologist
as performed with clinical examination and electromy-
graphy in all patients complaining of myalgia. Open biopsy
f the vastus lateralis was performed in two patients, and 8
m-thick frozen sections were cut and stained using hema-
oxylin and eosin, Gomori’s trichrome method, periodic
cid-Schiff, and Sudan black using routine protocols. En-
yme histochemical preparations for succinic dehydroge-
ase, cytochrome oxidase, nicotinamide adenine dinucle-
tide dehydrogenase tetrazolium reductase, adenosine
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AMP Kinase Disease in Hypertrophic Cardiomyopathy March 15, 2005:922–30riphosphatase at pH 4.2, 4.3, and 9.4, phosphorylase, acid
hosphatase, and myoadenylate deaminase were made using
outine methods. A small sample of muscle was fixed in
lutaraldehyde and processed for electron microscopy using
tandard protocols. Semi-thin (1-m) resin sections were
ut and stained using toluidine blue for light microscopy; 70
m sections were cut, mounted on copper grids, and stained
ith uranyl acetate and lead citrate for electron microscopy.
ata analysis. Statistical analysis was performed using
PSS statistical software (version 10.0, SPSS Inc., Chicago,
llinois). All data are expressed as mean values SD (range)
r frequency (percentage). Differences between mean values
ere determined using the unpaired or paired Student t test,
here appropriate. The chi-square test was used for com-
arisons between dichotomous variables. Survival estimates
ere calculated by Kaplan-Meier method.
ESULTS
enetic results. No sequence variations in PRKAG2 were
ound in the first cohort of HCM patients randomly
elected for mutation analysis (n  100). In the second,
elected cohort of HCM patients with electrophysiologic
bnormalities (n  100), only one additional proband was
ound to be carrying a PRKAG2 mutation: a missense
utation predicted to cause the amino acid substitution
rg302Gln was identified in a 30-year-old (H9.1) with
CM and WPW syndrome. He received a pacemaker at
he age of 20 years after developing symptomatic atrioven-
ricular block. Full clinical screening of his family showed
o abnormalities, and the mutation was found to have arisen
e novo on genetic screening and haplotype analysis of the
edigree. This mutation has been previously described by
ur group in four members of another unrelated family
family H363) with HCM and WPW syndrome. In family
304, we have previously reported 26 members with an
rg488Ile mutation in PRKAG2 (2). We have subse-
uently identified 14 additional mutation carriers from this
amily, who are also described here.
These two mutations are proposed to be disease-causing
s they were not seen in unaffected family members, nor in
00 normal controls, and they altered residues that are
onserved through evolution. In addition, prior functional
tudies and murine models incorporating these mutations
ave suggested pathogenicity (4).
linical results. In the 45 mutation carriers from three
amilies in this study (Table 1), disease expression was
haracterized by accessory pathways on surface ECG, pro-
ressive conduction disease, and progressive LVH on echo-
ardiography. In addition, myalgia and a proximal myop-
thy were documented.
NITIAL PRESENTATION. Mean age at initial presentation
as 24 years (median 20 years, range 9 to 55 years).
wenty-two (48%) gene carriers had palpation, 7 (15%) had
re-syncope, and 13 (28%) syncope. At presentation, 11
24%) had exertional dyspnea, of which 10 had New York oeart Association functional class 2 symptoms and 1 had
lass 3 symptoms. Nine patients (20%) had chest pain.
even patients (15%) had symptoms of myalgia and or
roximal muscle weakness, with calf and thigh muscle pain
articularly after exercise. Four had epilepsy (including three
f those with myalgia) with generalized tonic-clonic seizures
oorly controlled by medication. Fourteen gene carriers
31%) were asymptomatic, at a mean age of 26 years (range
0 to 47 years).
CG AND HOLTER AT INITIAL PRESENTATION. A short PR
nterval (120 ms) was present in 30 (66%). Ventricular
re-excitation including the presence of a delta wave was
dentified in 27 (60%) patients; ECG criteria for LVH were
resent in 35 (77%) patients. Thirteen had right bundle
ranch block, 7 left bundle branch block, and depolarization
bnormalities with a bizarre QRS configuration (Fig. 1)
ere noted in 17. There was 100% penetrance for ECG
bnormalities (LVH with re-polarization change, abnormal
RS, short PR interval, and/or delta waves) by the age of 18
ears. Sixteen (35%) patients had evidence of sinus node
isease, with chronotropic incompetence on exercise testing.
hirteen (28%) patients had paroxysmal or established atrial
brillation, and two had paroxysmal supraventricular tachy-
ardia. There were three (6%) patients with documented
on-sustained ventricular tachycardia on Holter monitoring
two with severe LVH on echocardiography 30 mm).
CHOCARDIOGRAPHIC CHARACTERISTICS. Left ventricu-
ar hypertrophy was present in 32 of 41 patients (78%) over
he age of 18 years. Of those patients with hypertrophy,
ean MLVWT was 21 mm (median 18 mm, range 13 to 45
m). The pattern of hypertrophy varied within families and
ithin immediate kinships; 12 patients had asymmetric
eptal hypertrophy, 19 had concentric hypertrophy, and 1
ad distal hypertrophy. The distribution of hypertrophy was
able 1. Clinical Features of Individual Families With
RKAG2 Mutations
Mutation (Family)
Asn488lle
(H304)
Arg302Gln
(H363)
Arg302Gln
(H9)
umber affected n  40 n  4 n  1
ge at diagnosis (yrs) 19 (3–45) 26 (15–38) 20
symptomatic 14 (35%) 0 0
yncope 5 (12.5%) 4 (100%) 1 (100%)
yalgia 7 (18%) 0 0
re-excitation 23 (58%) 4 (100%) 0
F/SVT 12 (30%) 3 (75%) 0
SVT 3 (7.5%) 0 0
VH by echo (adults) 28 (70%) 3 (75%) 1 (100%)
ean MLVWT (mm) 24 (13–45) 16 (15–16) 32
PM 12 (30%) 4 (100%) 1 (100%)
troke 3 (7.5%) 0 0
CD 1 0 0
rogressive LVH (adults) 13 (57%) 0 0
F  atrial fibrillation; echo  echocardiography; LVH  left ventricular hypertro-
hy; MLVWT  maximal left ventricular wall thickness; NSVT  non-sustained
entricular tachycardia; PPM  pacemaker; SCD  sudden cardiac death; SVT 
upraventricular tachycardia.ften eccentric; in three patients, maximal hypertrophy was
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March 15, 2005:922–30 AMP Kinase Disease in Hypertrophic Cardiomyopathyt the inferolateral wall, and in three others at the infero-
osterior wall. One patient had complete systolic anterior
otion of the mitral valve with left ventricular outflow tract
bstruction of 65 mm Hg, another had partial systolic
nterior motion of the mitral valve with no outflow tract
bstruction. No other patient had systolic anterior motion
f the mitral valve or a gradient 30 mm Hg. A restrictive
itral inflow Doppler pattern (E/A ratio 2.0, DT 150
s) was seen in 12 of 32 patients (37%). No patient had a
elayed relaxation pattern. Mean left atrial diameter was 34
m (range 21 to 54 mm). Nine of 41 subjects over the age
f 18 years (22%) had normal left ventricular cavity dimen-
ions, normal left ventricular wall thickness, and normal left
trial dimensions, at a mean age of 27 years (median 27
ears, range 18 to 37 years).
XERCISE CAPACITY. Mean percent predicted peak oxygen
onsumption achieved (measured in 13 patients) was 76%
range 38% to 114%). There were no exercise-induced ventric-
lar arrhythmias. Three patients had an abnormal blood
ressure response to exercise, with a failure to raise systolic
lood pressure 25 mm Hg from baseline. None of these
hree patients had asymmetric septal hypertrophy, diastolic
ysfunction by echocardiography, or LVH 15 mm.
LECTROPHYSIOLOGIC STUDY. Eight patients underwent
ormal electrophysiologic study because of symptomatic
ustained palpitations with a surface ECG consistent with
PW syndrome. The Wenckeback point was reduced in
our patients at a mean cycle length of 520 ms, but
ntravenous adenosine produced atrioventricular block in
nly two patients. Four accessory pathways were identified,
igure 1. Electrocardiogram of a 28-year-old mutation carrier showing ch
ypertrophy by voltage, short PR interval, delta wave, and bizarre QRS chree posteroseptal, one mid-septal, with effective refractory leriods of 200 to 290 ms. No reentry tachycardias were
nduced. Ventricular fibrillation was induced in one patient
uring high right atrial pacing. Three pathways were suc-
essfully ablated by radiofrequency ablation.
KELETAL MYOPATHY. Seven patients (15%) complained of
yalgia, during or immediately after short bursts of aerobic
xercise. Neurological assessment showed evidence of prox-
mal weakness; electromyography was normal in five pa-
ients. Light microscopy of the vastus lateralis showed that
uscle fibers were of normal size (40 to 90 m). Ragged red
bers were demonstrated throughout the biopsy using
omori’s trichrome preparation, succinic dehydrogenase,
nd NADH-TR and were predominantly found to be type
fibers. No cytochrome-oxidase-negative fibers were seen;
owever, the ragged red fibers were strongly stained in this
reparation (Fig. 2A). Although no excess glycogen was
vident on periodic-acid Schiff staining, examination of
emithin sections showed that several fibers contained a
ild excess of glycogen. Ultrastructural examination con-
rmed the presence of excess glycogen that occasionally
ppeared to be within mitochondria. As expected in the
ontext of ragged red fibers on histologic analysis, increased
umbers of mitochondria were found, although no mito-
hondrial paracrystaline inclusions were seen (Fig. 2B).
linical follow-up. Mean clinical follow-up was 12.2 years
median 12 years, range 1 to 41 years) with clinical exam-
nation, ECG, and echocardiographic studies repeated at
pproximately annual intervals. Survival at last follow-up
as 91%. There were four disease-related deaths. Three
ied from thromboembolic strokes secondary to atrial fibril-
ristic changes of adenosine monophosphate kinase disease: left ventricular
ration.ation (at age 55, 57, and 62 years), with poor compliance
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AMP Kinase Disease in Hypertrophic Cardiomyopathy March 15, 2005:922–30ith, or interruption of, anticoagulation in all three cases at
ime of stroke. A fourth patient died suddenly at the age of
7 years in 1994. He had massive LVH (MLVWT 45 mm)
nd previously documented non-sustained ventricular
achycardia. No patient underwent cardiac transplantation.
here were no non-fatal strokes. Two patients with myalgia
ad progressive symptoms, one with decreased power re-
uiring a wheelchair by the age of 46 years.
Twenty-four patients who were adults at time of initial
valuation exhibited significant ECG changes over time.
even patients developed complete atrioventricular block,
ve developed right bundle branch block, two left bundle
ranch block, and two had intermittent left bundle branch
lock and right bundle branch block. Right bundle branch
igure 2. (A) Frozen sections of skeletal muscle showing ragged red fiber
ytochrome oxidase (b) and succinic dehydrogenase (c) preparations. Fiber
.3). Bar in panel a represents 60 m in panels a, b, c, and d. (B) Ultras
he periphery of a muscle fiber (a). Glycogen is sometimes seen within mi
anel b. (C) Histology from the postmortem myocardium of the 27-year
xtensive vacuolation of myocytes (arrow), marked pleomorphism of nuclei,
egenerative changes in mitochondria (not shown).lock pattern changed from rsR to Rsr in three, and an cccentric pattern of intraventricular conduction delay 120
s was seen in six patients. Ten developed sinus node
isease with symptomatic bradycardia and/or chronotropic
ncompetence. New anterolateral T-wave inversion ap-
eared in two (without development of voltage criteria for
VH on ECG). QRS axis changed from normal to left axis
n three. An intermittent slurred upstroke (delta wave) was
ocumented in two patients. Figure 3 shows a spectrum of
CG change in adults, including ECG change in the
bsence of echocardiographic evidence of increased hyper-
rophy.
By the end of the study period, 17 of the 45 patients
38%) had pacemakers implanted (Fig. 4), 7 for atrioven-
ricular block, and 10 for symptomatic sinus bradycardia or
icated by arrows (a: Gomori’s trichrome) that are strongly stained in the
g shows that these fibers are darkly stained type 1 fibers (d: ATPase pH
ral examination shows an excess of mitochondria and glycogen (arrow) at
ndria (b, arrow). Bar in panel a represents 2 m in panel a and 1 m in
patient with sudden cardiac death reveals coarse interstitial fibrosis, with
inimal disarray (HE, 200). Electron microscopy showed non-specifics ind
typin
tructu
tocho
-old
and mhronotropic incompetence. Mean age of onset of symp-
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March 15, 2005:922–30 AMP Kinase Disease in Hypertrophic Cardiomyopathyigure 3. (A) Progressive electrocardiogram (ECG) change in adenosine monophosphate kinase disease: ECG of 19-year-old female with a short PR and
eft ventricular hypertrophy (upper) who developed a new rsR pattern and left-axis deviation by the age of 28 (lower). Her echocardiogram showed
aximum left ventricular wall thickness (MLVWT) increasing from 14 to 17 mm. (B) Electrocardiogram of a 28-year-old female at time of initial
ssessment (upper), with an intraventricular conduction delay (IVCD) and a slurred QRS upstroke, which by age 35 years (lower) shows the development
f a more widespread and bizarre IVCD, with diffuse T-wave inversion. This patient had no documented echocardiographic progression of disease, with
LVWT stable at 11 to 12 mm.
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AMP Kinase Disease in Hypertrophic Cardiomyopathy March 15, 2005:922–30omatic conduction disease was 38 years (median 37 years,
ange 16 to 56 years). In three cases the development of
trioventricular block was sudden and clinically dramatic
ith a slow ventricular escape rhythm and causing vascular
ollapse requiring urgent pacing.
Implantable cardioverter defibrillators (ICDs) were im-
lanted for primary prophylaxis in two patients (age 20 and
2 years) with massive LVH, one of whom had ventricular
brillation during high right atrial pacing at electrophysi-
logic study. Neither experienced ICD discharge during a
ean of 31 months follow-up.
Of the 30 adults in this study at baseline, four died, and
hree had no echocardiographic follow-up. Of the 23 adults
ssessed serially at a median of 10 years (range 7 to 12 years),
3 (57%) had progressive LVH (from a mean of 15 4 mm
o 20 3 mm, p 0.002), there was no change in 6 (26%),
nd regression of hypertrophy was seen in 4 (17%). Figure
shows change in maximal LVWT by echocardiography in
dults. Five patients developed massive hypertrophy 30
m. Two of these patients progressed to a dilated phase
ith wall thinning. Five patients developed impaired sys-
olic function at follow-up with reduced percent fractional
hortening 25 (mean 21%). There was no apparent effect
f beta-blocker therapy (n  2), angiotensin-converting
nzyme inhibitor therapy (n  1), or systemic hypertension
n 1) on progression. No patient underwent myectomy or
lcohol septal ablation.
ISCUSSION
he AMPK is a ubiquitous enzyme system that appears to
ct as a “fuel gauge” in cells. An increase in the AMP/ATP
atio triggers activation of the AMPK, with subsequent
hosphorylation of a number of downstream targets switch-
ng off those energy (ATP)-utilizing pathways that are not
ssential for cell survival and switching on catabolic energy-
enerating pathways. PRKAG2 encodes the 2 regulatory
Figure 4. Relationship of age to cumulative pacemaker implantation.ubunit, but the effects of the disease-causing mutations
i
yescribed in this gene on the overall activity of AMPK
ppear to vary with the experimental model used (14,15).
he mutations are predicted to uncouple cellular metabo-
ism to some extent from the ambient energetic needs. The
eposition of a glycogen-like substance, amylopectin, in the
earts of mice overexpressing transgenic mutant PRKAG2
uggests that the cell may be inappropriately sensing a
educed ATP requirement (4). In this model, focal amy-
opectin deposition leads to the development of echocardio-
raphic LVH and of accessory pathways, demonstrated to
onsist of bands of glycogen-filled myocytes running
hrough the annulus fibrosis, which normally insulates the
tria from ventricles (4). The myocardial histological hall-
ark of PRKAG2 mutations in man is widespread intra-
ellular vacuolation and interstitial fibrosis, with deposition
f amylopectin (Fig. 2C), similar to the histological appear-
nce seen in other forms of glycogen storage disorder that
imic HCM.
The identification of disease-causing mutations in
RKAG2 led to speculation that defects in energy utiliza-
ion may provide a final common pathway in the still poorly
nderstood pathophysiology of HCM (7,16). The substan-
ial duration of follow-up in this study provides insight into
he natural history of cardiac pathology in AMPK disease.
here was slowly progressive, occasionally massive, increase
n wall thickness in the majority of patients followed over a
ean of 12 years. In contrast, the hypertrophy in established
dult sarcomeric HCM rarely progresses once established
nd often undergoes gradual thinning (17). However, in
nherited disorders of metabolism such as Anderson-Fabry’s
isease and in the glycogen storage diseases the pattern of
yocardial thickening also is slowly progressive (18,19).
revious studies have concentrated on the role of deposition
f amylopectin as a major mechanism of disease in AMPK.
owever, the fact that ECG change occurred in the absence
f ultrastructural or echocardiographic changes (Figs. 3A
nd 3B), and that skeletal muscle histology shows mito-
hondrial proliferation with minimal excess glycogen (Figs.
A and 2B), suggests that deposition may not be the only
echanism of disease, and that these cellular systems might
e uniquely susceptible to derangements in ATP handling.
ndeed, vacuolation in the two skeletal muscle samples is
emarkable by its absence. In addition, widespread coarse
igure 5. Change in maximum left ventricular wall thickness (MLVWT)
n adults from first assessment as adults with a median follow-up of 10
ears (range 7 to 12 years).
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March 15, 2005:922–30 AMP Kinase Disease in Hypertrophic Cardiomyopathybrosis is present in cardiac histology in this study, suggest-
ng myocyte cell death and replacement fibrosis as seen in
he context of energy mismatch in sarcomeric HCM. Thus,
assive deposition of storage product is not the only mech-
nism of disease (4), and defects in ATP sensitivity may lead
o a more widespread disruption of cellular energetics.
nterestingly, there is some evidence of phenotypic hetero-
eneity between families. For example, all gene carriers in
he two families with the Arg302Gln mutation (H9 and
363) required pacing at a mean age of 25 years. Families
ith the Arg531Gly mutation have associated pre-
xcitation, atrial fibrillation, but no reported cardiac hyper-
rophy (1), whereas Asn488Ile mutations are associated
ith cardiac hypertrophy in 78%. The Exon5:InsLeu mu-
ation produces a phenotype dominated by cardiac failure
nd pre-excitation (7). Whether this phenotypic heteroge-
eity is a result of the specific effects of individual mutations
emains to be seen. Although the molecular consequences of
his defect are poorly understood, the disorder is of con-
inuing interest in attempts to clarify mechanisms of hyper-
rophy in sarcomeric HCM, which may involve a response
o disruption of cellular energy hemostasis (7).
This is the first systematic study of AMP kinase disease that
escribes a skeletal myopathy as part of the disorder. This
undamentally alters our understanding of the disease, and may
elp redefine it as a systemic metabolic disorder. The obser-
ation of severe myalgia and proximal skeletal myopathy
ighlights the extracardiac clinical manifestations of PRKAG2
utations, and further supports the notion of a significant role
or impaired energy utilization in the pathogenesis of the
isorder. Analogous mutations in porcine PRKAG cause
lycogen accumulation in pig skeletal muscle, which renders it
ommercially unusable (15). The proportion of AMPK activity
n human cardiac muscle accounted for by the gamma2 subunit
s more than twice the proportion provided for in skeletal
uscle (20), which may account for the milder skeletal muscle
linical manifestations in vivo in this study. Importantly, this
esemblance to other storage disorders involves not only skel-
tal muscle involvement, but also the pattern of cardiac
onduction disease and ventricular pre-excitation. These
echanistic themes, coupled with the substantial clinical over-
ap between AMP kinase disease and primary mitochondrial
isorders, suggest a common metabolic susceptibility of the
ormal development of the atrioventricular ring, and the
ardiac conduction system. Metabolic effects have also been
mplicated to some extent in cardiac disease associated with
amin A/C or emerin mutations and myotonic dystrophy (21).
picture of a more fundamental disruption of cellular ener-
etics is emerging, in which specific cellular substrates are
ffected by disparate genetic defects, and produce a comparable
henotype of skeletal myopathy, cardiac conduction disease,
nd cardiomyopathy. The relative rarity of AMP kinase disease
ocumented in this study (albeit the screening method used is
nly 95% sensitive) should stimulate the ongoing search for
ore candidate genes in this context.
Finally, the current study suggests that the major clinicalomplication of AMPK disease is progressive cardiac con-
uction disease, with 17 of 45 patients (38%) needing
acing by the age of 38. Accessory-pathway-mediated
rrhythmias were not a major clinical feature, despite the
dentification of delta waves in 66% of patients. Atrial
rrhythmias were common and associated with embolic
troke. Ventricular arrhythmias were infrequent and were
ssociated with hypertrophy, and implantable cardioverter
efibrillators implantation may be indicated for those with
onventional HCM risk factors. The electrophysiologic
haracteristics of accessory pathway and atrioventricular
odal tissue were idiosyncratic: documented pathways with-
ut any inducible tachycardias, and atrioventricular block on
acing but no response to intravenous adenosine.
onclusions. Comprehensive clinical assessment with
ong-term follow-up shows that AMP kinase disease is
haracterized by premature conduction disease requiring
acing, progressive cardiac hypertrophy, and a skeletal
yopathy, consistent with a systemic metabolic storage
isease. Disease-causing mutations in PRKAG2 are rare in
CM, even in the setting of complex HCM phenotypes
ith conduction disease and WPW syndrome. Passive
eposition of amylopectin does not account for all clinical
eatures, and further study of the effects of fundamental
isruption of ATP utilization may clarify the pathophysi-
logy of cardiac disorders with premature conduction dis-
ase and/or myopathy.
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